Prostate Cancer - Results from #1320

Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection. February 21, 2024

Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer. February 21, 2024

Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study. February 21, 2024

Variability in prostate cancer detection among radiologists and urologists using MRI fusion biopsy. February 20, 2024

Evaluation of Proclarix in the diagnostic work-up of prostate cancer. February 20, 2024

Low PSA radiographic disease progression on C11-choline PET. February 20, 2024

Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition. February 20, 2024

Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies. February 20, 2024

Prostate Cancer Screening Uptake in Transgender Women. February 19, 2024

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. February 19, 2024

PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways. February 19, 2024

Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments. February 19, 2024

Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy. February 19, 2024

A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. February 16, 2024

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong S February 16, 2024

eHealth literacy in prostate cancer: A systematic review. February 16, 2024

The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. February 16, 2024

Novel hormonal therapy versus standard of care-A registry-based comparative effectiveness evaluation for mCRPC-patients. February 16, 2024

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. February 16, 2024

Initial COBRA Results: Clarity’s SAR-bisPSMA Is Safe and Highly Effective in Detecting Tumours in Prostate Cancer Patients. Phase 3 Planning Underway. February 15, 2024

Page 67 of 1435